A share price of Incyte Corp. [INCY] is currently trading at $64.38, up 1.77%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The INCY shares have gain 3.81% over the last week, with a monthly amount drifted -1.24%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Incyte Corp. [NASDAQ: INCY] stock has seen the most recent analyst activity on July 02, 2024, when BMO Capital Markets downgraded its rating to a Underperform and also revised its price target to $48 from $52. Previously, Deutsche Bank started tracking the stock with Hold rating on May 23, 2024, and set its price target to $55. On April 23, 2024, Cantor Fitzgerald initiated with a Neutral rating. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $81 on February 23, 2024. JMP Securities downgraded its rating to a Mkt Perform. Leerink Partners upgraded its rating to Outperform for this stock on December 13, 2023, but kept the price target unchanged to $78. In a note dated December 04, 2023, Guggenheim upgraded an Buy rating on this stock but restated the target price of $86.
Incyte Corp. experienced fluctuations in its stock price throughout the past year between $50.27 and $70.36. Currently, Wall Street analysts expect the stock to reach $81 within the next 12 months. Incyte Corp. [NASDAQ: INCY] shares were valued at $64.38 at the most recent close of the market. An investor can expect a potential return of 25.82% based on the average INCY price forecast.
Analyzing the INCY fundamentals
Trailing Twelve Months sales for Incyte Corp. [NASDAQ:INCY] were 3.86B which represents 9.34% growth. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at 0.0%, Pretax Profit Margin comes in at 0.09%, and Net Profit Margin reading is 0.03%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.02 and Total Capital is 0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 63.35 points at the first support level, and at 62.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 65.09, and for the 2nd resistance point, it is at 65.81.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Incyte Corp. [NASDAQ:INCY] is 1.92. In addition, the Quick Ratio stands at 1.84 and the Cash Ratio stands at 0.74. Considering the valuation of this stock, the price to sales ratio is 3.21, the price to book ratio is 4.12 and price to earnings (TTM) ratio is 181.40.
Transactions by insiders
Recent insider trading involved Stein Steven H, EVP & Chief Medical Officer, that happened on Aug 12 ’24 when 11608.0 shares were sold. Officer, STEVEN STEIN completed a deal on Aug 12 ’24 to buy 11608.0 shares. Meanwhile, EVP, GMAPPS Iyengar Vijay K sold 15571.0 shares on Jul 25 ’24.
